EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The IAP Protein Family, SMAC Mimetics and Cancer Treatment

Alex Philchenkov, Koh Miura

Critical Reviews™ in Oncogenesis · 2016 · 21 (3-4) · 185-202

DOI: 10.1615/critrevoncog.2016017032 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Critical Reviews™ in Oncogenesis, 2016. Verfasst von Alex Philchenkov und 1 weiteren Autor:innen. Beteiligte Einrichtung: R. E. Kavetsky Institute of Experimental Pathology, Oncology & Radiobiology Kyiv, Ukraine. Die Arbeit wurde bisher 21-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since the acquired resistance of cells to apoptosis is one of the major hallmarks of cancer, the endogenous inhibitors of apoptosis can be regarded as promising targets in the design of anticancer therapeutics. In addition to their antiapoptotic activity, inhibitor of apoptosis proteins (IAPs) are able to regulate numerous other cell functions, including proliferation, differentiation, and migration, as well as proinflammatory and immune responses. Study of the IAP family as target molecules in targeted therapies has recently focused on SMAC mimetics as synthetic IAP antagonists that have been under development as promising therapeutics. To overview the background of IAP proteins and to focus on the development of SMAC mimetics, the present review first looks at the mechanisms of IAP proteins' antiapoptotic activities and those for controlling those activities; then the SMAC mimetics, including birinapant, LCL161, and DEBIO1143/AT-406, and their clinical trials are introduced. To further clarify the processes to exert the efficacies of SMAC mimetics, it is necessary to determine therapeutic biomarkers that predict and assess them, which may include caspases and factors in the TNFα pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsApoptosisAzocinesBenzhydryl CompoundsCell ProliferationDipeptidesHumansIndolesInhibitor of Apoptosis ProteinsNeoplasmsThiazoles

Substanzen

Antineoplastic AgentsAzocinesBenzhydryl CompoundsDipeptidesIndolesInhibitor of Apoptosis ProteinsLCL161N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxami…Thiazolesbirinapant

Autor:innen und Institutionen

  • R. E. Kavetsky Institute of Experimental Pathology, Oncology & Radiobiology Kyiv, Ukraine.
  • Department of Surgery, Miyagi Cancer Center, Natori, Miyagi, Japan.

Zitieren

APA

Philchenkov, A., & Miura, K. (2016). The IAP Protein Family, SMAC Mimetics and Cancer Treatment. Critical Reviews™ in Oncogenesis, 21(3-4), 185-202. https://doi.org/10.1615/critrevoncog.2016017032

Vancouver

Philchenkov A, Miura K. The IAP Protein Family, SMAC Mimetics and Cancer Treatment. Critical Reviews™ in Oncogenesis. 2016;21(3-4):185-202. doi:10.1615/critrevoncog.2016017032

BibTeX
@article{Philchenkov2016,
  author = {Philchenkov, Alex and Miura, Koh},
  title = {The IAP Protein Family, SMAC Mimetics and Cancer Treatment},
  journal = {Critical Reviews™ in Oncogenesis},
  year = {2016},
  volume = {21},
  number = {3-4},
  pages = {185--202},
  doi = {10.1615/critrevoncog.2016017032}
}
Kostenlos starten →